Ftse Mib
33.739,90
-0,08%
DAX
19.848,77
-0,34%
S&P 500
6.037,59
1,06%
NASDAQ
20.020,36
-0,05%
Bitcoin
96.078,46
0,40%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Pharvaris NV (PHVS) Pharvaris NV (PHVS) Notizie

Pharvaris NV

PHVS
19,50
0,67 (3,56%)
27 Dic 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
02/12/202422:27EDGAR2Form 144 - Report of proposed sale of securities
13/11/202422:12EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/11/202422:10GLOBEPharvaris Reports Third Quarter 2024 Financial Results and..
12/11/202412:50GLOBEPharvaris to Participate in the Guggenheim Healthcare..
31/10/202421:27EDGAR2Form 144 - Report of proposed sale of securities
24/10/202422:23EDGAR2Form 144 - Report of proposed sale of securities
24/10/202414:00GLOBEPharvaris Presents Clinical and Non-Clinical Data Supporting..
16/10/202412:50GLOBEPharvaris Announces Data Highlighting Deucrictibant for the..
15/10/202412:50GLOBEPharvaris to Host Virtual Investor Event on October 23, 2024
03/10/202412:50GLOBEPharvaris Announces Data Highlighting Deucrictibant for the..
25/9/202412:50EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
23/9/202412:51EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/9/202422:27EDGAR2Form 144 - Report of proposed sale of securities
20/9/202400:45EDGAR2Form 144 - Report of proposed sale of securities
20/9/202400:44EDGAR2Form 144 - Report of proposed sale of securities
19/9/202422:27EDGAR2Form 144 - Report of proposed sale of securities
16/9/202422:46EDGAR2Form 144 - Report of proposed sale of securities
05/9/202412:51EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/9/202412:50GLOBEPharvaris Provides Business Update and Expands Development..
05/9/202412:49GLOBEPharvaris Presents Deucrictibant Long-Term Extension Data..
05/9/202412:48GLOBEPharvaris Presents Data at the Bradykinin Symposium 2024
28/8/202412:50GLOBEDeucrictibant Clinical, Real-World, Nonclinical, and..
14/8/202412:51EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/8/202412:50GLOBEPharvaris Reports Second Quarter 2024 Financial Results and..
11/6/202412:52EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/6/202412:50GLOBEPharvaris Announces Annual Meeting of Shareholders
04/6/202422:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/6/202412:50GLOBEPharvaris Highlights Properties of Deucrictibant in Data..
24/5/202423:04EDGAR2Form 144 - Report of proposed sale of securities
22/5/202423:54EDGAR2Form 144 - Report of proposed sale of securities
13/5/202412:50GLOBEPharvaris to Present Clinical and Nonclinical Data at..
08/5/202422:11EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/5/202422:10GLOBEPharvaris Reports First Quarter 2024 Financial Results and..
10/4/202422:10GLOBEPharvaris Reports Fourth Quarter and Full Year 2023..
10/4/202422:08GLOBEPharvaris Appoints David Nassif, J.D., as Chief Financial..
04/4/202412:50GLOBEPharvaris to Present Deucrictibant Clinical Data at the CIIC..
18/3/202411:50GLOBEPharvaris Announces Phase 3 Clinical Study Design for..
11/3/202418:51EDGAR2Form 144 - Report of proposed sale of securities
06/3/202422:40EDGAR2Form F-3ASR - Automatic shelf registration statement of..
06/3/202422:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/3/202412:50GLOBEPharvaris to Present Deucrictibant Clinical Data at Upcoming..
05/3/202412:50GLOBEPharvaris to Participate in the Leerink Global Biopharma..
22/2/202412:50GLOBEPositive Results from CHAPTER-1 Phase 2 Study of..
16/2/202412:51EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/2/202412:50GLOBEPharvaris Announces Extraordinary Meeting of Shareholders
07/2/202422:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/2/202422:46EDGAR2Form 144 - Report of proposed sale of securities
26/1/202412:50GLOBEPharvaris to Present at the WSAAI Annual Meeting 2024
22/1/202413:35DJNPharvaris Says FDA Lifted Clinical Hold on Application for..
22/1/202412:51EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
Apertura: 18,59 Min: 18,55 Max: 20,00
Chiusura: 18,83

La tua Cronologia

NASDAQ
PHVS
Pharvaris NV
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network